Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.63 |
| ▸ | CTSS | P25774 | 1/20 | 0.55 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3046058 | 0.95 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3046050 | 0.95 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12018629 | 0.95 | CTSB (0.65) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13248870 | 0.92 | CTSB (0.61) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3052749 | 0.92 | CTSB (0.61) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3052744 | 0.92 | CTSB (0.61) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12018606 | 0.90 | CTSB (0.79) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3045944 | 0.86 | CTSB (0.50) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2383508 | 0.85 | CTSB (0.53) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2383497 | 0.85 | CTSB (0.53) | CTSBCTSSADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | claimed |
| US-7671032-B2 | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2010-03-02 | — | — | US | disclosed |